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Bioinformatics approaches applied to healthcare data are a 
crucial tool to identifying potential drug- drug interactions (DDIs). 
Researchers must exercise caution in their interpretation of 
results from big data studies, as structure and function of 
databases may generate bias. Assessment of results may be 
hampered by the lack of gold standard positive and negative 
interacting drug pairs. However, integrating clinical data mining 
with mechanistic understanding of drug action can promote 
confidence in DDI predictions.
Adverse drug events (ADEs) are a major 
cause of morbidity and mortality, resulting 
in over 3.5 million outpatient clinic and 
790,000 emergency department visits an-
nually in the United States.1 DDIs lead to 
increased risk of ADEs, and ADE risk in-
creases with higher drug burden. Individuals 
taking five or more medications have 1.88- 
times greater risk of ADE than individuals 
taking one drug.1 Some DDI mechanisms, 
such as cytochrome P450 induction or in-
hibition, can be detected during early drug 
development. However, many DDIs are not 
apparent during the controlled, relatively 
small clinical studies performed during drug 
development. Postmarketing pharmacovigi-
lance studies using real- world data and the 
application of data mining and bioinfor-
matics approaches have become vehicles 
for detecting novel drug- drug interactions 
leading to adverse drug events (DDI- ADE).
The expansion of big data resources in 
health care and science has provided a rich 
source of information for pharmacovigi-
lance studies to investigate DDIs. A variety 
of real- world data have been employed to 
identify and predict potential DDIs, includ-
ing clinical, social media, physiochemical, 
and biological data. Many studies rely on 
electronic health records (EHRs), health-
care claims data, or spontaneous reporting 
systems (SRS), such as the US Food and 
Drug Administration’s (FDA’s) Adverse 
Events Reporting System (FAERS), to pro-
vide real- world data on medication use and 
adverse events. Other studies have applied 
natural language processing and machine 
learning algorithms to published literature, 
social media (e.g., Instagram and Twitter), 
or biological and chemical databases (e.g., 
KEGG, DrugBank, and PubChem) to 
predict DDIs. For a more detailed descrip-
tion of data and bioinformatics approaches 
utilized in translational DDI research, the 
reader is directed to recently published 
reviews.2,3
CLINICAL DATABASES
EHR, claims databases, and other large 
healthcare databases provide a rich source 
of information regarding DDI- ADE risk. 
However, there are also limitations to big 
data that must be considered during design 
and interpretation of DDI- ADE studies.
First, it is critical to understand the in-
tended purpose of the databases. SRS, 
such as the FAERS and Vigibase, collect 
information from patients, healthcare 
professionals, and pharmaceutical com-
panies regarding drug–adverse event re-
ports. While SRS provide large quantities 
of data, the quality and details provided by 
each record can vary substantially. The use 
of EHRs is nearly universal in the United 
States and many other countries. Primary 
uses of EHRs include patient care deliv-
ery, management and support processes, 
patient self- management, and financial 
and other administrative processes.4 EHR 
systems provide several advantages over 
SRS, including collection of information 
over time and review by healthcare pro-
fessionals. Healthcare claims databases 
available from the Center for Medicare and 
Medicaid Services (CMS) or other insur-
ance companies provide structured infor-
mation on pharmacy or medical claims, 
including diagnosis codes. Similar to EHR 
data, claims data provide longitudinal in-
formation. Unlike EHR data, claims data 
provide information across healthcare sys-
tems. However, there is still potential for 
patients to be lost to follow- up as they may 
move between healthcare insurers.
Second, the structure of the database in-
fluences analyses. FAERS data are gathered 
from voluntary or mandatory reports to 
MedWatch. While MedWatch report forms 
are largely free text, most researchers utilize 
the structured FAERS data. The conversion 
from unstructured to structured data may 
lead to loss of information. EHR data are 
collected from various sources and stored 
in either structured or unstructured (free 
text) formats. Common structured data 
include laboratory results, diagnosis codes 
(e.g., International Classification of Diseases 
(ICD) codes), billing data (e.g., Current 
Procedural Terminology (CPT) codes), 
medication orders, and some demographic 
data. Unstructured data include clinical 
notes and reports from imaging or patholog-
ical studies. Health claims data are in a struc-
tured format, based on specific billing codes.
Finally, one must be aware of biases inher-
ent in the design of these databases.5 Reports 
are voluntarily entered into SRS, which may 
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 106 NUMBER 1 | JULY 2019 73
PERSPECTIVES
lead to underreporting or overreporting of 
particular events. A number of factors may 
lead to varying rates of reporting. For in-
stance, the time a drug has been on the mar-
ket may substantially impact rates of adverse 
event reports, with more reports expected 
within the first few years after a drug comes 
to market. Media coverage can also lead to 
increased awareness of a given adverse event, 
prompting individuals to report additional 
cases. It is also more likely that serious or ex-
tremely rare adverse events will be reported. 
Conversely, when data already support a link 
between a drug and adverse event, it may 
be less likely to be reported.5 On the other 
hand, EHRs were designed with the goal of 
improving clinical care, not as research tools. 
Thus, data may not be input to adequately 
address research questions. EHR data may 
also be incomplete. Patients transfer between 
healthcare providers or systems, leading to 
missing data or loss to follow- up. Importantly 
for DDI- ADE studies, there are many defi-
ciencies in collecting and reporting of med-
ication use and adherence data in EHRs. 
Medication orders and pharmacy records 
only capture prescribing patterns and deliv-
ery of prescription medications to patients. 
Although refill data may provide an indica-
tion of patient persistence and adherence to 
medications, this is an imperfect measure and 
not suitable for evaluating medications, such 
as antibiotics, used to treat acute conditions. 
Additionally, use of over- the- counter med-
ications and supplements are only assessed 
clinically through patient interview and 
inconsistently documented within EHRs. 
Thus, studies of DDIs using EHRs are largely 
limited to interactions between prescription 
medications, reflecting potential but not 
necessarily actual use of the drug by patients. 
Like EHR data, claims data are collected 
longitudinally. While they are better able to 
capture information across providers (i.e., 
various pharmacies and physician groups), 
loss to follow- up is common as individuals 
may move between insurance providers.
DEFINING POSITIVE AND NEGATIVE 
RESULTS
In evaluating DDIs identified using biomed-
ical informatics approaches, it is important 
to consider the definition of a positive and 
negative result. Data mining approaches 
often focus on high sensitivity, often at 
the cost of specificity. This leads to a large 
number of false positive findings. However, 
assessment of a data mining approach by 
the identification of true positive (or gold 
standard) DDIs may also not be valid due to 
selective prescribing or reporting patterns. 
Medication alerts with higher severity are 
more likely to be acted upon by clinicians. In 
the case of DDI research, clinicians may be 
less likely to use drugs together that have a 
known high risk of interaction. Thus, it may 
be difficult to distinguish “known positive” 
interactions in clinical databases. This may 
lead to discrepancies between DDIs identi-
fied from literature, gene, or pathway analy-
ses and those identified in clinical databases. 
Additionally, there is no gold- standard defi-
nition of a “positive” or “negative” DDI, as 
there is no one recognized standard resource 
for DDIs, and DDI reports vary among dif-
ferent compendia. At best, positive results 
from DDI studies can be grouped into three 
categories: previously reported known in-
teractions; unknown but mechanistically 
plausible; and unknown with no obvious 
mechanism. While previously reported 
known interactions may be interpreted as 
“true positive DDI,” it is nearly impossible to 
define a “true negative DDI.” For instance, 
we have identified a potential increased risk 
for myopathy in individuals taking azithro-
mycin with zolendroante.6 A careful review 
of the literature and other drug interaction 
resources failed to uncover reported inter-
actions or mechanisms of increased risk of 
myopathy due to these drugs. However, it 
may be that these drugs have not previously 
been evaluated in this context. Yet another 
explanation for this finding may be that 
these drugs are commonly coadministered 
with other agents that are associated with 
increased myopathy. Without a definitive 
controlled study evaluating the two drugs 
in combination, it is unfeasible to classify a 
potential DDI as a false positive.
The definition of a “true positive” and 
“true negative” may also be difficult to distin-
guish in biomedical literature. An initial step 
in natural language processing and machine 
learning methodologies for text mining is the 
manual annotation of a corpus to develop a 
data set of true positive and true negative 
phrases. These corpora are subsequently used 
for training and testing of algorithms prior to 
deployment. During the development of a 
full- text corpus of clinical pharmacokinetic 
data, pairs of annotators in my lab reviewed 
a total of 23,372 phrases from 170 full texts. 
Annotators disagreed upon classification of 
nearly 20% of the phrases (S. Quinney, un-
published data). This is consistent with inter- 
annotator agreement of complex concepts 
reported by other groups.7–9 Disagreements 
among annotators may be mitigated by 
additional experts in the field (e.g., a third 
annotator) or excluded from the corpus. 
However, it should be noted that exclusion 
may bias downstream analyses.
ALTERNATIVE APPROACHES TO 
SUPPORT FINDINGS FROM CLINICAL 
DATA
These limitations should not discourage 
investigators from utilizing big data re-
sources, as they provide a rich resource 
of clinical data relating to drug- ADEs. 
However, these approaches should not be 
used in isolation. Associations identified in 
EHRs or SRS do not equate to causation. 
Some medications may be associated with 
an adverse event due to their use in diag-
nosing or treating the ADE. For instance, 
we have identified an association between 
gadolinium-based contrast agents and 
myopathy in the FAERS.6 While there is 
the potential for these agents to cause my-
opathy, a more likely explanation of this 
association is that contrast agents were em-
ployed during imaging studies during the 
diagnosis of the myopathy. To establish 
causation between DDIs and risk of ADE, 
studies must incorporate additional meth-
ods. Some researchers have utilized path-
way analyses to develop drug- gene- drug 
links among potential DDIs.2,3,7 In vitro 
exploration of potential DDI mechanisms, 
such as cytochrome P450 or transporter 
induction or inhibition, coupled with 
pharmacokinetic in vitro in vivo extrapo-
lation approaches may also be employed.2
CONCLUSION
Bioinformatics approaches are an important 
weapon in our arsenal for DDI assessment. 
When utilized as part of a comprehensive 
approach that incorporates mechanistic un-
derstanding through drug- gene interactions 
or in vitro investigations, detection of poten-
tial DDIs through clinical data becomes a 
powerful discovery tool. However, research-
ers must be aware of limitations within 
these databases, such as reporting bias or 
inability to distinguish temporal patterns. 
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Collaboration with a clinical expert may 
provide insight into the database structure 
and practice for inputting data. Clinicians 
can also assist with interpretation of poten-
tial DDIs, especially if they seem ambiguous. 
While bioinformatics approaches for detec-
tion of potential DDIs may be beset with a 
number of challenges and limitations, its 
potential for generating new knowledge and 
identifying novel DDIs among drugs with 
no known mechanism of interaction is excit-
ing. These studies, when viewed as hypothe-
sis generating, may uncover novel pathways 
of pharmacological action and DDIs, fur-
ther propelling translational investigations.
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Model- informed drug development (MIDD) is a powerful approach 
to increase efficiency in drug development, impact regulatory 
outcomes, and improve drug benefit–risk balance.1,2 A critical 
factor for the continued growth of MIDD is a regulatory 
environment with the capacity, expertise, and transparency that 
increases stakeholder confidence in MIDD approaches.3 The US 
Food and Drug Administration (FDA) MIDD Paired Meeting Pilot 
Program was established to address this need by providing a 
dedicated avenue for regulatory interaction on MIDD issues.
MOTIVATION FOR THE FDA’S 
MIDD PAIRED MEETING PILOT 
PROGRAM
The FDA has applied and accepted MIDD 
approaches during the regulatory review of 
new drug applications or biologic license 
applications for decades.4 However, appli-
cation of MIDD has been largely opportu-
nistic, and in- depth engagement between 
regulatory and drug development scientists 
on MIDD issues during the investigational 
new drug stage has historically been lim-
ited. Based on our past observations, we be-
lieve that consistent and successful MIDD 
application occurs when there is:
• direct engagement between the FDA 
and drug development scientists with 
expertise in developing and applying 
MIDD approaches
• socialization of MIDD concepts among 
multidisciplinary teams to ensure clar-
ity around the issues to be addressed, 
and value and limitations of the MIDD 
approaches, and
• shared decision making among FDA sci-
entists, led by subject matter experts, to 
